![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 6, 4056-4061, February 8, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the § Horticultural Sciences Department, University
of Florida, Gainesville, Florida 32611, ¶ Department of Chemistry
and Biochemistry, The Institute for Cellular and Molecular Biology,
University of Texas at Austin, Austin, Texas 78712, and
** Department of Biochemistry, Vanderbilt University School
of Medicine, Veterans Affairs Medical Center, Nashville, Tennessee
37212
Received for publication, November 6, 2001, and in revised form, November 21, 2001
One-carbon flux into methionine and
S-adenosylmethionine (AdoMet) is thought to be controlled
at the methylenetetrahydrofolate reductase (MTHFR) step. Mammalian
MTHFRs are inhibited by AdoMet in vitro, and it has been
proposed that methyl group biogenesis is regulated in vivo
by this feedback loop. In this work, we used metabolic engineering in
the yeast Saccharomyces cerevisiae to test this hypothesis.
Like mammalian MTHFRs, the yeast MTHFR encoded by the MET13
gene is NADPH-dependent and is inhibited by AdoMet in
vitro. This contrasts with plant MTHFRs, which are
NADH-dependent and AdoMet-insensitive. To manipulate flux
through the MTHFR reaction in yeast, the chromosomal copy of
MET13 was replaced by an Arabidopsis MTHFR
cDNA (AtMTHFR-1) or by a chimeric sequence (Chimera-1) comprising the yeast N-terminal domain and the AtMTHFR-1 C-terminal domain. Chimera-1 used both NADH and NADPH and was insensitive to AdoMet, supporting the view that the C-terminal domain is responsible for
AdoMet inhibition. Engineered yeast expressing Chimera-1 accumulated 140-fold more AdoMet and 7-fold more methionine than did the wild-type and grew normally. Yeast expressing AtMTHFR-1 accumulated 8-fold more
AdoMet. This is the first in vivo evidence that the AdoMet sensitivity and pyridine nucleotide preference of MTHFR control methylneogenesis. 13C labeling data indicated that glycine
cleavage becomes a more prominent source of one-carbon units when
Chimera-1 is expressed. Possibly related to this shift in
one-carbon fluxes, total folate levels are doubled in yeast cells
expressing Chimera-1.
Methylenetetrahydrofolate reductase
(MTHFR)1 catalyzes the
reduction of 5,10-methylenetetrahydrofolate (CH2-THF) to
5-methyltetrahydrofolate (CH3-THF), which serves as a
methyl donor for the synthesis of methionine. Methionine gives rise to
S-adenosylmethionine (AdoMet), which is used for numerous
methylation reactions. Because the MTHFR reaction commits the methyl
group carried by THF to methyl group biogenesis, the regulation of
MTHFR is crucial for one-carbon (C1) metabolism in all
organisms (1, 2). The MTHFR reaction in mammalian liver is
NADPH-dependent and is consequently physiologically irreversible due to the high cytosolic NADPH/NADP ratio and the large
standard free energy change for the reduction of CH2-THF (3-5). This reaction therefore has the potential to deplete the cytosolic CH2-THF pool (1, 2). Mammalian MTHFRs have
been shown to be inhibited by AdoMet (6, 7), and this sensitivity is
considered to be a key regulatory feature that prevents
CH2-THF depletion (1, 2, 6). However, there is no direct
evidence for the existence of this regulation in vivo.
Plant MTHFRs are NADH-dependent and are thought to be
cytosolic. Due to the high cytosolic NAD/NADH ratio (8), the MTHFR reaction in planta is likely to be reversible, obviating a
need for regulation by AdoMet (9). Consistent with this, plant MTHFRs are AdoMet-insensitive (9). Both Saccharomyces cerevisiae
and Schizosaccharomyces pombe have two divergent copies of
the MTHFR gene. The MTHFR genes of S. cerevisiae
(MET12 and MET13) have been cloned and shown to
encode functional enzymes (10), but neither their pyridine nucleotide
requirement nor their AdoMet sensitivity has been investigated. Strains
in which MET13 is disrupted require methionine for growth.
However, met12 disruptants have no methionine requirement,
and overexpressing Met12p does not eliminate the methionine requirement
of met13 disruptants. These data indicate that the Met13p
isozyme provides most of the MTHFR activity in yeast cells (10).
All known eukaryotic MTHFRs comprise an N-terminal domain that contains
the catalytic site and a C-terminal domain that is implicated in the
regulation of enzymatic activity (11-13). The C-terminal domain of
mammalian MTHFRs contains the AdoMet-binding site and is therefore
considered responsible for the enzyme's sensitivity to this effector
(11-14). The function of the C-terminal domain of plant MTHFRs, which
are insensitive to AdoMet, is unknown (9). The
NADH-dependent, AdoMet-insensitive MTHFR of
Escherichia coli (MetF) lacks the C-terminal domain
(15-17).
In this study, we first showed that S. cerevisiae Met13p is
NADPH-dependent and inhibited by AdoMet, like mammalian
MTHFRs. We then constructed a chimeric yeast-plant MTHFR (Chimera-1)
and characterized its pyridine nucleotide dependence and AdoMet
sensitivity. Finally, we used metabolically engineered yeast strains
expressing AdoMet-insensitive MTHFRs (AtMTHFR-1 or Chimera-1) to
establish the importance of the AdoMet feedback loop in
vivo.
Chemicals and Reagents--
[14C]Formaldehyde (53 mCi/mmol) was purchased from PerkinElmer Life Sciences PerkinElmer Life
Sciences, and
(6R,6S)-[methyl-14C]CH3-THF
(56 mCi/mmol) was obtained from Amersham Biosciences, Inc.; specific
radioactivities were adjusted to the desired values with unlabeled
compound. THF and (6R,6S)-CH3-THF
were obtained from Schircks Laboratories (Jona, Switzerland).
[13C]Formic acid (99% 13C) was from
Cambridge Isotope Laboratories (Andover, MA). Glucose-6-phosphate dehydrogenase (recombinant Leuconostoc mesenteroides enzyme)
and all other biochemicals were from Sigma. Glass beads were
acid-etched.
CHIMERA-1 DNA Construction and Overexpression in
Yeast--
CHIMERA-1 was constructed using gene splicing by
overlap extension (18). DNA fragments were amplified by high-fidelity
PCR using recombinant Pfu DNA polymerase (Stratagene). The
Met13p N-terminal domain (residues 1-333) was amplified from the
MET13-pVT101-U plasmid using primers
5'-CATGAAGATCACAGAAAAATTAGAGC-3' (forward) and
5'-GGTTTGCCCAGAAGATAGGTCTGACTTCC-3' (reverse). The AtMTHFR-1 C-terminal
domain (residues 327-592) was amplified from the AtMTHFR1-pVT103-U plasmid using primers 5'-CCTATCTTCTGGGCAAACCGTCCAAAGAGC-3' (forward) and 5'-TGCACTGCAGTCAAGCAAAGACAGAGAAG-3' (reverse). The two amplified fragments were mixed in a 1:1 ratio and joined by PCR using
MET13 forward and AtMTHFR-1 reverse primers to generate the
CHIMERA-1 DNA. The CHIMERA-1 DNA was inserted
into yeast expression vector pVT103-U. The resulting construct was
introduced by electroporation into E. coli DH10B cells.
After verification by sequencing, the construct was introduced as
described previously (10) into yeast strain RRY3 ( Yeast Strains, Plasmids, and Growth
Conditions--
Synthetic minimal medium (YMD medium) contained 0.7%
yeast nitrogen base without amino acids (DIFCO Bacto®),
2% glucose, and the following supplements when indicated:
L-serine (375 mg/liter), L-leucine (30 mg/liter), L-histidine (20 mg/liter), L-tryptophan (20 mg/liter), uracil (20 mg/liter), glycine
(20 mg/liter), formate (250 mg/liter), and L-methionine (20 mg/liter). Cultures were grown at 30 °C in a rotary shaker at 250 rpm. Pre-sporulation medium contained 0.8% Bacto-yeast extract, 0.3%
Bacto-peptone, 10% glucose, and 2% Bacto-agar. Minimal sporulation
medium contained 1% potassium acetate and 2% Bacto-agar. The S. cerevisiae strains used were DAY4 (ser1 ura3-52 trp1 leu2
his4), RRY1 (ser1 ura3-52 trp1 leu2 his4
Enzyme Isolation and Assays for MTHFR Activity--
Yeast cells
were grown, washed, and extracted as described previously (9).
Desalted, concentrated extracts were also prepared as described
previously (9). MTHFR activity was assayed in the reductive direction
using the NAD(P)H-CH2-THF oxidoreductase radioassay
described previously (9). The assay buffer was 100 mM
potassium phosphate, pH 7.2. Unless otherwise noted, substrates were
saturating, and product formation was proportional to enzyme concentration and time.
Determination of AdoMet and Methionine--
Yeast cells were
grown in YMD medium supplemented with glycine, formate, leucine,
histidine, tryptophan, and uracil. Cells were harvested in mid-log
growth and washed with water. To measure AdoMet, the cell pellet (300 mg wet weight) was resuspended in 500 µl of water and lysed by
vortexing with glass beads for 5 × 30 s. Protein from
clarified lysates was precipitated with ethanol (final concentration,
70%) at Preparation of Extracts for NMR Analysis--
Yeast cells were
grown in 500-ml cultures supplemented with [13C]formate
(250 mg/liter) and unlabeled glycine, harvested at an A600 of 3-5, and washed with water. Extracts
were prepared by resuspending the cell pellet from the whole culture in
500 µl of water and lysing with glass beads by continuous vortexing
at 4 °C for 20-30 min. Lysates were clarified by centrifugation, and proteins were precipitated with ethanol as described above. The
deproteinized supernatant was dried in vacuo and redissolved in 1 ml of D2O.
NMR Analysis--
NMR spectra were obtained on a Varian
Unity-Inova Spectrometer with a 1H frequency of 500 MHz and
a 13C frequency of 125 MHz. 13C data were
collected with an acquisition time of 1.3 s with a 3-s delay and
90° pulse angle. Two-level composite pulse was used for proton
decoupling with a power level of 48 dB during acquisition and 40 dB during delay. A total of 200-2000 scans of 64,000 data points were
acquired over a sweep width of 25 kHz. Data processing included
exponential line broadening of 1 Hz.
[methyl-13C]AdoMet was quantified by comparing
NMR peak heights with a standard sample of known concentration.
Folate Determination--
Yeast strains were grown, harvested,
and washed as described for AdoMet and methionine determination.
Pelleted cells were suspended in twice their wet weight of extraction
buffer (50 mM HEPES, 50 mM
2-(cyclohexylamino)ethanesulfonic acid, 0.2 M
2-mercaptoethanol, and 2% (w/v) sodium ascorbate, pH 7.9). Glass beads
were added at 1.5 times the wet weight of the pellet. The samples were
heated at 100 °C for 10 min and lysed by vortexing for 4 min. After
centrifugation (20,000 × g, 30 min), supernatants were
decanted, their volumes were measured, and they were stored at
NADPH Dependence and AdoMet Sensitivity of Yeast MTHFR
Met13p--
Recombinant Met13p was overexpressed in RRY3, a
met12 met13 double disruptant that totally lacks MTHFR
activity and is a methionine auxotroph (10). The pyridine nucleotide
preference and AdoMet sensitivity of recombinant Met13p were tested by
measuring enzyme activity radiometrically in the forward (reductive)
direction in 100 mM potassium phosphate buffer, pH 7.2 (9).
Met13p was found to be strictly NADPH-dependent and to be
inhibited by AdoMet (Fig. 1A).
Activity with NADH as reductant was below the detection limit of the
assay (<2% of activity with NADPH).
Construction of a Chimeric Yeast-Plant MTHFR--
A chimeric MTHFR
(Chimera-1) was constructed by fusing the N-terminal (catalytic) domain
of Met13p to the C-terminal domain of a plant MTHFR (AtMTHFR-1 from
Arabidopsis thaliana; Ref. 9). The domains were spliced
together by overlap extension PCR (18) within a short, conserved amino
acid sequence (VRPIFW) that is immediately downstream of a region
identified as the interdomain bridge in mammalian MTHFRs (12). Fig.
2A shows the domain structure of the chimeric enzyme and its parents schematically; Fig.
2B shows the sequence of the Chimera-1 polypeptide.
Complementation of a Yeast Pyridine Nucleotide Preference and AdoMet Insensitivity of
Chimera-1--
Recombinant Chimera-1 overexpressed in yeast strain
RRY3 was tested for pyridine nucleotide preference and AdoMet
sensitivity as described above for Met13p. Chimera-1 was found to use
both NADH and NADPH (Fig. 1B), which was unexpected because
its yeast and plant parents use either one or the other (Fig. 1,
A and C). However, as anticipated, Chimera-1 was
totally insensitive to AdoMet (Fig. 1B), like the plant
enzyme that contributes its C-terminal region (Fig. 1C).
Kinetic Properties of Met13p, AtMTHFR-1, and
Chimera-1--
Velocity versus [S] plots for both Met13p
and AtMTHFR-1 showed substrate inhibition by CH2-THF that
was especially marked in the case of Met13p (Fig.
4). The Km and
Ki values of these two enzymes for
CH2-THF were accordingly calculated as described by Cleland
(23). Chimera-1 showed no inhibition by CH2-THF within the
range tested (Fig. 4). Its Km values for
CH2-THF were therefore estimated from Hanes plots; these
values were similar whether NADH or NADPH was the reductant and fell midway between those of the parent enzymes (Table
I). Because the activities of Met13p and
AtMTHFR-1 were inhibited by CH2-THF, apparent
Km values of these enzymes for NADPH and NADH were
compared with those of Chimera-1 using a nonsaturating
CH2-THF concentration of 50 µM (Table I). The
apparent Km values of Chimera-1 for both NADPH and
NADH were closer to that of AtMTHFR than to that of Met13p.
Construction of Yeast Strains with a Chromosomal Copy of CHIMERA-1
or AtMTHFR-1--
To study how AdoMet sensitivity and pyridine
nucleotide specificity impact the function of MTHFR in vivo,
we engineered strains in which the coding sequence of AtMTHFR-1 or
Chimera-1 replaced that of the chromosomal MET13 gene. The
introduced sequences were thus present as single chromosomal copies
under the control of the native promoter, ensuring an expression level
comparable to that of MET13. Replacement of the
MET13 open reading frame with Chimera-1 and AtMTHFR-1 gave
strains SCY4 and SCY6, respectively. The growth rates of these strains
in YMD medium supplemented with serine, histidine, leucine, tryptophan,
and uracil were similar to that of the wild-type (doubling times,
2.5 ± 0.2 h). Thus, both the chimeric enzyme and the plant
enzyme complemented the methionine requirement when expressed from the
chromosomal MET13 promoter.
Levels of AdoMet and Methionine in DAY4, SCY4, and SCY6 Yeast
Strains--
AdoMet and free methionine were determined by HPLC. In
the experiment shown in Fig. 5, strain
SCY6 expressing the AdoMet-insensitive, NADH-dependent
AtMTHFR-1 accumulated 8-fold more AdoMet than the DAY4 strain
expressing the native Met13p enzyme. Strain SCY4 expressing the
AdoMet-insensitive, NADH- or NADPH-dependent enzyme
Chimera-1 accumulated even more AdoMet (140-fold more AdoMet than DAY4) (Fig. 5A). Along with the greatly elevated AdoMet level,
strain SCY4 accumulated 7-fold more methionine than DAY4 (Fig.
5B). AdoMet hyperaccumulation was seen in SCY4 cultures
harvested at a range of cell densities; its magnitude varied from
75-fold to 254-fold above wild-type in four independent experiments
(data not shown).
Origin of the C1 Units Used for AdoMet
Synthesis--
The yeast strains used in this study are all ser1
strains that are blocked at phosphoserine aminotransferase and thus
require serine for growth; glycine (or glycine plus formate) can
substitute for serine. Use of ser1 Intracellular Folate Levels in Yeast Strains DAY4, SCY4, and
SCY6--
The pools of 10-formyltetrahydrofolate,
5-formyltetrahydrofolate, 5-CH3-THF, and THF were
determined by HPLC combined with microbiological assay (21, 22). The
most abundant folate in all strains was 5-CH3-THF,
constituting Characterization of yeast Met13p shows that its properties are
very much like those of mammalian MTHFRs: Met13p is AdoMet-sensitive, NADPH-dependent, and susceptible to substrate inhibition by
CH2-THF. Photoaffinity labeling evidence indicates that the
AdoMet-binding site of porcine and human MTHFRs lies in the C-terminal
domain, within a stretch of about 30 residues starting 30 residues
after the junction between the domains (12, 14). The sequence of Met13p
in this region is far closer to that of human MTHFR (41% identity and
66% similarity) than to that of the AdoMet-insensitive plant enzyme
AtMTHFR-1 (20% identity and 44% similarity). Outside this region, all
three MTHFRs share about ~40% identity. The primary structure of
Met13p is thus consistent with the AdoMet-binding site being in the
proximal part of the C-terminal domain.
The effects of allosteric inhibition by AdoMet and pyridine nucleotide
preference on the in vivo control of MTHFR activity were
assessed in metabolically engineered yeast strains SCY6 and SCY4.
Strain SCY6 expresses an AdoMet-insensitive, NADH-dependent plant enzyme, AtMTHFR-1. Strain SCY4 expresses the chimeric enzyme Chimera-1, comprising the Met13p N-terminal domain and the AtMTHFR-1 C-terminal domain. Chimera-1 is an active, AdoMet-insensitive enzyme
that uses both NADPH and NADH. The AdoMet insensitivity of Chimera-1 is
consistent with the C-terminal domain of MTHFR being responsible for
sensitivity to AdoMet. Because the determinants for pyridine nucleotide
binding are located in the N-terminal domain (27), the loss of
selectivity for NADPH in Chimera-1 could reflect distortion in the
tertiary structure of its Met13p N-terminal domain caused by fusion to
a foreign C terminus. Another possibility is that interaction between
the catalytic and C-terminal domains guides the specificity of the
enzyme for its pyridine nucleotide substrate. In either case, it is
noteworthy that porcine MTHFR can use NADH as a substrate if the assay
is carried out in the presence of phosphate, for this shows that the
enzyme's pyridine nucleotide specificity can be readily altered (28). The apparent lack of substrate inhibition of Chimera-1 by
CH2-THF may likewise be explained by distorted tertiary
structure or by modified domain interaction.
The overaccumulation of methionine and AdoMet in yeast strains
engineered with the AdoMet-insensitive AtMTHFR-1 or Chimera-1 (8- and
140-fold more AdoMet, respectively) provides the first in
vivo evidence that allosteric inhibition of MTHFR by AdoMet controls the commitment of C1 units to methylneogenesis.
The more dramatic effect of Chimera-1 may be explained by its ability
to utilize NADPH as well as NADH (Fig.
6). The redox state of the NAD(P) pool is
known to affect the reversibility of the MTHFR reaction. In mammals,
the almost completely reduced NADP pool (NADPH/NADP ratio of
~107) ensures that the MTHFR reaction is practically
irreversible (3-5). In plants, the NAD pool is highly oxidized
(NADH/NAD ratio of ~10 The finding that expressing an NADH-dependent,
AdoMet-insensitive plant MTHFR in yeast causes methionine and AdoMet
overaccumulation raises the question of what prevents this from
occurring in plants. Plants have the S-methylmethionine
cycle, an auxiliary feature exclusive to plant C1
metabolism (30, 31). In this apparently futile cycle, AdoMet donates a
methyl group to methionine, giving S-methylmethionine.
S-Methylmethionine then donates a methyl group to
homocysteine, yielding two molecules of methionine. The net effect of
the cycle is thus to convert AdoMet back to methionine. In
vivo radiolabeling data and metabolic modeling have recently indicated that the S-methylmethionine cycle serves to stop
accumulation of unutilized AdoMet and that it may be the main mechanism
whereby plants achieve short-term control of AdoMet levels (31).
Because S. cerevisiae does not have this cycle, AdoMet might
be expected to accumulate in yeast expressing the plant enzyme, as in
fact occurs.
The 140-fold hyperaccumulation of AdoMet has no apparent ill-effect on
yeast growth, at least under our culture conditions. A likely reason is
that most of the excess AdoMet is sequestered in the vacuole and hence
excluded from the metabolically active pool, as occurs when AdoMet is
overproduced in yeast cultured with a high level of methionine in the
medium (32). It should be noted that although AdoMet hyperaccumulation
was a robust phenomenon in strain SCY4 grown as we describe in medium
containing formate and glycine, it did not occur when these supplements
were replaced by serine. The basis for this effect is now being investigated.
In wild-type yeast, the dominant methylated products are
phosphatidylcholine head groups in membranes (~12 µmol methyl units g Consistent with the above inference, and equally surprising, strain
SCY4 expressing Chimera-1 showed a doubling of total cellular folate
content compared with the wild-type. This folate pool expansion could
be a response to the shift in C1 fluxes occasioned by
unregulated AdoMet synthesis. Whatever the mechanism, the data imply
that cross-talk between C1 metabolism and folate synthesis
or degradation is an important factor in control of intracellular
folate levels.
*
This work was supported in part by the Florida Agricultural
Experimental Station, by an endowment from the C. V. Griffin, Sr.
Foundation, and by grants from the National Science Foundation (to
A. D. H.), the National Institutes of Health (to D. R. A.), and the
Department of Veterans Affairs, National Institutes of Health DK32189,
Clinical Nutrition Research Unit DK26657 (to D. W. H.) and approved
for publication as Journal Series no. R-08516.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF441241.
Published, JBC Papers in Press, November 29, 2001, DOI 10.1074/jbc.M110651200
The abbreviations used are:
MTHFR, 5,10-methylenetetrahydrofolate reductase (EC 1.5.1.20 and 1.7.99.5);
AdoMet, S-adenosyl-L-methionine;
CH2-THF, 5,10-methylenetetrahydrofolate;
CH3-THF, 5-methyltetrahydrofolate;
THF, (6R,6S)-tetrahydrofolic acid;
HPLC, high
performance liquid chromatography.
Metabolic Engineering in Yeast Demonstrates That
S-Adenosylmethionine Controls Flux through the
Methylenetetrahydrofolate Reductase Reaction in Vivo*
§,
¶,
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
met12
met13) for enzyme studies and into strain SCY1
(MET12
met13) for complementation.
met13), and RRY3 (ser1 ura3-52 trp1 leu2 his4
met12
met13) (9). The plasmids were
pVT101-U and pVT103-U (19), pVT101-U containing the yeast
MET13 gene (10), and pVT103-U containing a cDNA encoding
MTHFR from the plant Arabidopsis thaliana (AtMTHFR-1) (9). The CHIMERA-1-pVT103-U plasmid
was used as template to construct strain RRY5 (ser1 ura3-52 trp1
leu2 his4
met12
met13::CHIMERA-1) by
gene replacement. The CHIMERA-1 open reading frame was
amplified with primers 5'-CAACAGGTTCATGCCACTGG-3' and
5'-ACAATGGAAAAGGAAGGAGCAAAATCTGGTAAAAATTCTCGGAGATCAAGCA-3'. The 1.4-kbp
CHIMERA-1 fragment was gel-purified using the QIAquick gel
extraction kit (Qiagen) and used to transform the methionine-requiring strain RRY3. Transformants were selected by methionine prototrophy indicating successful integration of the CHIMERA-1 fragment.
Correct integration at the disrupted met13 locus was
confirmed by PCR. SCY1 (ser1 ura3-52 trp1 leu2 his4
met13) and SCY4 (ser1 ura3-52 trp1 leu2 his4
met13::CHIMERA-1) were constructed by
crossing RRY1 and RRY5. The resulting diploids were sporulated by
incubation on pre-sporulation medium at 30 °C for 2 days, followed
by transfer to minimal sporulation medium supplemented with serine,
uracil, tryptophan, leucine, and histidine and incubation for 5-7 days at 25 °C. Tetrads were dissected as described previously (10). SCY6
(ser1 ura3-52 trp1 leu2 his4
met13::AtMTHFR-1) was constructed by gene
replacement. The AtMTHFR-1 open reading frame was amplified with primers
5'-AACAGAACCACCACAGTTACTACTACAACCACATCGCAATATGAAGGTGGTTGATAAGAT-3' and
5'-TGACAATTCTGTTAAAGAACTGTTATCGTTGTCTGTGTTATCAAGCAAAGACAGAGAAGA-3'. The
amplified 1.9-kbp DNA fragment was used to transform the
methionine-requiring strain RRY1; transformants were selected by
methionine prototrophy and confirmed by PCR as described above.
20 °C for 15 min and removed by centrifugation
(13,000 × g, 20 min, 4 °C). The supernatant was evaporated to dryness in vacuo, dissolved in water, and
analyzed by isocratic HPLC (20) using a Waters Spherisorb ODS2 column (4.6 × 250 mm) with a Beckman Coulter System Gold 126 Solvent Module and 168 Detector and a Rheodyne 7725i Injector. The mobile phase
was 50 mM NaH2PO4, 10 mM 1-heptanesulfonic acid, and 20% methanol, pH 4.4;
column temperature was 22 °C, flow rate was 0.8 ml
min
1, and run time was 30 min. To determine methionine,
200-mg samples of wet cells were suspended in 180 µl of water and
heated at 100 °C for 5 min. After cooling on ice, cells were
extracted essentially as described above, except that protein was
precipitated with 5-sulfosalicylic acid (final concentration, 3.5%).
The deproteinized samples were submitted to Biosynthesis Inc.
(Lewisville, TX) for amino acid analysis using a Beckman 7300 analyzer.
70 °C until analysis. Folate species were separated by HPLC
and quantified using the Lactobacillus casei microbiological
assay (21, 22).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (24K):
[in a new window]
Fig. 1.
Pyridine nucleotide preferences and
S-adenosylmethionine sensitivities of recombinant
MTHFRs. Desalted crude extracts of RRY3 (
met12
met13) yeast cells expressing Met13p (A), Chimera-1
(B), or AtMTHFR-1 (C) were assayed for
NAD(P)H-CH2-THF oxidoreductase activity using NADH or NADPH
(200 µM) as reductant, plus or minus 1 mM
AdoMet; CH2-THF concentration was 0.5 mM.
Extracts were preincubated for 15 min at 24 °C with buffer or AdoMet
before the assays. Data are means ± S.E. (n
3).

View larger version (61K):
[in a new window]
Fig. 2.
The primary structure of Chimera-1 and its
parent enzymes. A, schematic representations of
Chimera-1 and its parents, Met13p (black) and AtMTHFR-1
(white). The pyridine nucleotide specificity of each enzyme
is indicated. Chimera-1 comprises the N-terminal domain of Met13p and
the C-terminal domain of AtMTHFR-1. The gray bar marks the
hydrophilic bridge region between the domains, and the white
triangle shows the position of the AdoMet-binding site identified
by photoaffinity labeling of mammalian MTHFR (11, 13). B,
amino acid sequence of Chimera-1. The sequence from Met13p is in
black, and the sequence from AtMTHFR-1 is in
gray.
met13 Mutant by CHIMERA-1--
The
CHIMERA-1 DNA was cloned into the yeast expression vector
pVT103-U and introduced into strain SCY1 (MET12
met13). A MET12+ strain was used
to avoid any possible growth effects of a met12 mutation.
The transformation yielded methionine-independent colonies whose growth
was comparable with that of the wild-type strain DAY4, or SCY1
transformed with MET13-pVT101-U (Fig.
3). No complementation was observed with
the vector alone, and retransformation of SCY1 with rescued plasmid
containing CHIMERA-1 restored methionine prototrophy,
confirming that the complementation is due to the plasmid-encoded
chimeric enzyme (data not shown). Arabidopsis MTHFR
(AtMTHFR-1), expressed from pVT103-U, was previously shown to
complement the methionine requirement of a yeast met13
mutation (9).

View larger version (60K):
[in a new window]
Fig. 3.
Functional complementation of yeast MTHFR
mutants by Chimera-1. Similar numbers of cells of DAY4 (wild-type)
(1), SCY1 (MET12
met13) (2), or
SCY1 transformed with pVT101-U containing MET13
(3) or pVT103-U containing CHIMERA-1
(4) were plated on synthetic minimal medium plus or minus
methionine. Strain SCY4, whose chromosomal copy of MET13 is
replaced by CHIMERA-1, is shown (5).

View larger version (20K):
[in a new window]
Fig. 4.
Dependence of recombinant MTHFR activity on
CH2-THF concentration. Desalted extracts of RRY3
(
met12
met13) yeast cells expressing Met13p,
AtMTHFR-1, or Chimera-1 were assayed for NAD(P)H-CH2-THF
oxidoreductase activity using an NADH or NADPH concentration of 100 µM and CH2-THF concentrations of 10-1500
µM. Enzyme activities are expressed as a percentage of
the maximum activity obtained for each. Maximum activities (in nmol
min
1 mg
1 protein) were as follows: Met13p,
12.1; AtMTHFR-1, 27.9; and Chimera-1, 92.2. Only the values obtained
with NADPH as reductant are shown for Chimera-1; values with NADH were
very similar. All data shown are means of duplicate observations; S.E.
bars were smaller than the data points.
Apparent Km and Ki values of MTHFRs for NADPH, NADH,
and CH2-THF

View larger version (21K):
[in a new window]
Fig. 5.
AdoMet and methionine levels in yeast
expressing native Met13p or AdoMet-insensitive MTHFRs.
Intracellular levels of AdoMet (A) and free methionine
(B) in yeast strains DAY4 (MET13), SCY6
(
met13::AtMTHFR-1), and SCY4
(
met13::CHIMERA-1). Cells
were grown in synthetic minimal medium supplemented with glycine,
formate, leucine, histidine, tryptophan, and uracil and harvested at
A600 of 2.6-2.9. AdoMet data are means of
duplicate determinations on the same samples; S.E. values were
1% of
the means.
strains
allows controlled introduction of C1 units via the
cytosolic C1-THF synthase by providing formate or via the
mitochondrial glycine cleavage system by providing glycine (24). To
identify the source(s) of C1 units for production of
AdoMet, we determined the methyl-13C enrichment
of AdoMet in cultures supplemented with [13C]formate and
unlabeled glycine. The methyl-13C enrichment
under these conditions measures the relative contributions to methyl
group synthesis of C1 units originating from cytosol and
mitochondria (25, 26). The methyl-13C enrichment
values were 0.92 for the wild-type expressing Met13p and 0.54 for a
strain expressing Chimera-1. These data show that with wild-type
Met13p, >90% of AdoMet comes from [13C]formate, whereas
only 54% comes from [13C]formate when Chimera-1 replaces
Met13p. Thus, AdoMet hyperaccumulation is associated with a far greater
contribution from mitochondrial glycine cleavage to the C1
unit pool.
68% of the total folate pool. The other folates
(10-formyltetrahydrofolate, 5-formyltetrahydrofolate, and THF) each
represented <15% of the total in all strains (Table II). The most striking difference between
the strains was that SCY4 expressing Chimera-1 had more than twice the
total folate content of the wild-type strain DAY4 (156 versus 66 nmol g
1 wet weight), although the
relative amounts of the individual folates were essentially unchanged.
Another difference was that strain SCY6 expressing AtMTHFR-1 showed
only a slight increase in total folate relative to the wild-type DAY4,
but its 10-formyltetrahydrofolate and THF pools were doubled.
Folate levels in DAY4, SCY4, and SCY6 yeast strains
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
3) and is thought to make the
MTHFR reaction freely reversible (9). Reliable measurements of
cytosolic NAD(P)H/NAD(P) ratios in yeast are lacking. However, studies
with yeast cytosolic CH2-THF dehydrogenase show that the
NADP-dependent reaction is reversible in vivo,
whereas the NAD-dependent reaction runs only in the
oxidative direction (29). This indirect evidence suggests that the
yeast cytosolic NADP pool is far more reduced than the NAD pool. An AdoMet-insensitive MTHFR that is driven by the aggregate cytosolic NAD(P)H/NAD(P) ratio might therefore be expected to direct more C1 units to CH3-THF, and thence to AdoMet, than
one driven solely by the NADH/NAD ratio.

View larger version (37K):
[in a new window]
Fig. 6.
Proposed mechanism of AdoMet accumulation in
engineered yeast strains. A, in the wild-type strain
DAY4 expressing Met13p, the MTHFR reaction is irreversibly driven
toward CH3-THF formation by a high cytosolic NADPH/NADP, as
in mammals. AdoMet overaccumulation is prevented by allosteric feedback
inhibition (dotted line). B, in strain SCY6
expressing AtMTHFR-1, there is moderate AdoMet accumulation due to the
lack of feedback inhibition by AdoMet. The relatively low cytosolic
NADH/NAD ratio may limit the extent of this accumulation. C,
in strain SCY4 expressing Chimera-1, adding the capacity to use NADPH
as well as NADH to the lack of AdoMet feedback inhibition results in
more CH3-THF synthesis (and hence AdoMet accumulation)
because the aggregate cytosolic NAD(P)H/NAD(P) ratio (by which
Chimera-1 is driven) is higher than the NADH/NAD ratio.
1 wet weight) and protein-bound methionine (~14 µmol
g
1 wet weight, assuming 100 mg protein g
1
wet weight and a methionine content of 2 mol %) (33) (Proteome Analysis at EBI, 2001, www.ebi.ac.uk/proteome). The total level of methyl end products is therefore at least 26 µmol g
1
wet weight. In relation to this, the AdoMet pool in the wild-type strain DAY4 (31 nmol g
1 wet weight) is very small
(<0.2%). However, in the AdoMet-hyperaccumulating strain, the AdoMet
pool expands to ~4 µmol g
1 wet weight, which adds
~15% to the methyl budget. To investigate the source of the extra
methyl groups, we compared the 13C-enrichment of the AdoMet
methyl group in these two strains supplied with
[13C]formate and unlabeled glycine. In the wild-type,
DAY4, formate was the principal source of the AdoMet methyl group,
consistent with the previous data on the origin of choline methyl
groups in this strain (29). Surprisingly, even though the production of
methyl groups in the AdoMet-hyperaccumulating strain changed by only
~15%, the formate contribution to the AdoMet methyl group dropped
dramatically from >90% to 54%, with the remainder presumably coming
from glycine cleavage in the mitochondria. If we make the reasonable
assumption that AdoMet methyl-13C enrichment
faithfully reflects that of methionine, this finding shows that AdoMet
hyperaccumulation is associated with a profound change in the relative
importance of cytosolic and mitochondrial C1 fluxes.
![]()
FOOTNOTES
Both authors contributed equally to this work.
Present address: Dept. of Chemistry and Biochemistry, McMurry
University, McMurry Station, Box 158, Abilene, TX 79697.

To whom correspondence should be addressed: Horticultural
Sciences Dept., University of Florida, P. O. Box 110690, Gainesville, FL 32611. Tel.: 352-392-1928, Ext. 334; Fax: 352-392-6479; E-mail: adha@mail.ifas.ufl.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Appling, D. R.
(1991)
FASEB J.
5,
2645-2651[Abstract]
2.
Bagley, P. J.,
and Selhub, J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13217-13220 3.
Vanoni, M. A.,
and Matthews, R. G.
(1984)
Biochemistry
23,
5272-5279[CrossRef][Medline]
[Order article via Infotrieve]
4.
Green, J. M.,
Ballou, D. P.,
and Matthews, R. G.
(1988)
FASEB J.
2,
42-47[Abstract]
5.
Wohlfarth, G.,
and Diekert, G.
(1991)
Arch. Microbiol.
155,
378-381
6.
Jencks, D. A.,
and Matthews, R. G.
(1987)
J. Biol. Chem.
262,
2485-2493 7.
Kutzbach, C.,
and Stokstad, E. L. R.
(1971)
Biochim. Biophys. Acta
250,
459-477[Medline]
[Order article via Infotrieve]
8.
Heineke, D.,
Riens, B.,
Grosse, H.,
Hoferichter, P.,
Peter, U.,
Flugge, U.-I.,
and Heldt, H. W.
(1990)
Plant Physiol.
95,
1131-1137
9.
Roje, S.,
Wang, H.,
McNeil, S. D.,
Raymond, R. K.,
Appling, D. R.,
Shachar-Hill, Y.,
Bohnert, H. J.,
and Hanson, A. D.
(1999)
J. Biol. Chem.
274,
36089-36096 10.
Raymond, R. K.,
Kastanos, E. K.,
and Appling, D. R.
(1999)
Arch. Biochem. Biophys.
372,
300-308[CrossRef][Medline]
[Order article via Infotrieve]
11.
Matthews, R. G.,
Vanoni, M. A.,
Hainfeld, J. F.,
and Wall, J.
(1984)
J. Biol. Chem.
259,
11647-11650 12.
Goyette, P.,
Sumner, J. S.,
Milos, R.,
Duncan, A. M.,
Rosenblatt, D. S.,
Matthews, R. G.,
and Rozen, R.
(1994)
Nat. Genet.
7,
195-200[CrossRef][Medline]
[Order article via Infotrieve]
13.
Matthews, R. G.,
Sheppard, C.,
and Goulding, C.
(1998)
Eur. J. Pediatr.
157,
S54-S59
14.
Sumner, J.,
Jencks, D. A.,
Khani, S.,
and Matthews, R. G.
(1986)
J. Biol. Chem.
261,
7697-7700 15.
Katzen, H. M.,
and Buchanan, J. M.
(1965)
J. Biol. Chem.
240,
825-835 16.
Saint-Girons, I.,
Duchange, N.,
Zakin, M. M.,
Park, I.,
Margarita, D.,
Ferrara, P.,
and Cohen, G. N.
(1983)
Nucleic Acids Res.
11,
6723-6732 17.
Sheppard, C. A.,
Trimmer, E. E.,
and Matthews, R. G.
(1999)
J. Bacteriol.
181,
718-725 18.
Horton, R. M., Ho, S. N.,
Pullen, J. K.,
Hunt, H. D.,
Cai, Z.,
and Pease, L. R.
(1993)
Methods Enzymol.
217,
270-279[Medline]
[Order article via Infotrieve]
19.
Vernet, T.,
Dignard, D.,
and Thomas, D. Y.
(1987)
Gene (Amst.)
52,
225-233[CrossRef][Medline]
[Order article via Infotrieve]
20.
Wise, C. K.,
Cooney, C. A.,
Ali, S. F.,
and Poirier, L. A.
(1997)
J. Chromatogr. B Biomed. Sci. Appl.
696,
145-152[CrossRef][Medline]
[Order article via Infotrieve]
21.
Wilson, S. D.,
and Horne, D. W.
(1984)
Anal. Biochem.
142,
529-535[CrossRef][Medline]
[Order article via Infotrieve]
22.
Horne, D. W.,
and Patterson, D.
(1988)
Clin. Chem.
34,
2357-2359 23.
Cleland, W. W.
(1971)
in
The Enzymes
(Boyer, P. D., ed), Vol. 2
, pp. 35-43, Academic Press, New York and London
24.
Appling, D. R.,
Kastanos, E.,
Pasternack, L. B.,
and Woldman, Y. Y.
(1997)
Methods Enzymol.
281,
218-231[Medline]
[Order article via Infotrieve]
25.
Pasternack, L. B.,
Laude, D. A.,
and Appling, D. R.
(1994)
Biochemistry
33,
74-82[CrossRef][Medline]
[Order article via Infotrieve]
26.
Pasternack, L. B.,
Littlepage, L. E.,
Laude, D. A.,
and Appling, D. R.
(1996)
Arch. Biochem. Biophys.
326,
158-165[CrossRef][Medline]
[Order article via Infotrieve]
27.
Guenther, B. D.,
Sheppard, C. A.,
Tran, P.,
Rozen, R.,
Matthews, R. G,
and Ludwig, M. L.
(1999)
Nat. Struct. Biol.
6,
359-365[CrossRef][Medline]
[Order article via Infotrieve]
28.
Matthews, R. G.,
and Kaufman, S.
(1980)
J. Biol. Chem.
255,
6014-6017 29.
West, M. G.,
Horne, D. W.,
and Appling, D. R.
(1996)
Biochemistry
35,
3122-3132[CrossRef][Medline]
[Order article via Infotrieve]
30.
Mudd, S. H.,
and Datko, A. H.
(1990)
Plant Physiol.
93,
623-630 31.
Ranocha, P.,
McNeil, S. D.,
Ziemak, M. J., Li, C.,
Tarczynski, M. C.,
and Hanson, A. D.
(2001)
Plant J.
25,
575-584[CrossRef][Medline]
[Order article via Infotrieve]
32.
Schlenk, F.
(1965)
in
Transmethylation and Methionine Biosynthesis
(Shapiro, S. K
, and Schlenk, F., eds)
, pp. 48-65, The University of Chicago Press, Chicago and London
33.
Murakami, Y.,
Yokoigawa, K.,
Kawai, F.,
and Kawai, H.
(1996)
Biosci. Biotechnol. Biochem.
60,
1874-1876[Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
T. J. Vickers, G. Orsomando, R. D. de la Garza, D. A. Scott, S. O. Kang, A. D. Hanson, and S. M. Beverley Biochemical and Genetic Analysis of Methylenetetrahydrofolate Reductase in Leishmania Metabolism and Virulence J. Biol. Chem., December 15, 2006; 281(50): 38150 - 38158. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Krajinovic, S. Lamothe, D. Labuda, E. Lemieux-Blanchard, Y. Theoret, A. Moghrabi, and D. Sinnett Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia Blood, January 1, 2004; 103(1): 252 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Chan and D. R. Appling Regulation of S-Adenosylmethionine Levels in Saccharomyces cerevisiae J. Biol. Chem., October 31, 2003; 278(44): 43051 - 43059. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sarvari Horvath, C. J. Franzen, M. J. Taherzadeh, C. Niklasson, and G. Liden Effects of Furfural on the Respiratory Metabolism of Saccharomyces cerevisiae in Glucose-Limited Chemostats Appl. Envir. Microbiol., July 1, 2003; 69(7): 4076 - 4086. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Guinotte, M. G. Burns, J. A. Axume, H. Hata, T. F. Urrutia, A. Alamilla, D. McCabe, A. Singgih, E. A. Cogger, and M. A. Caudill Methylenetetrahydrofolate Reductase 677C->T Variant Modulates Folate Status Response to Controlled Folate Intakes in Young Women J. Nutr., May 1, 2003; 133(5): 1272 - 1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Kocsis, P. Ranocha, D. A. Gage, E. S. Simon, D. Rhodes, G. J. Peel, S. Mellema, K. Saito, M. Awazuhara, C. Li, et al. Insertional Inactivation of the Methionine S-Methyltransferase Gene Eliminates the S-Methylmethionine Cycle and Increases the Methylation Ratio Plant Physiology, April 1, 2003; 131(4): 1808 - 1815. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||